US Market Report for Middle Ear Implants 2017 - MedCore is a new market research publication announced by Reportstack. This market experienced moderate growth beginning in 2010, as middle ear implants received approval to treat mixed and conductive hearing loss and provide another treatment option for patients with damaged or malformed inner ears. Nevertheless, there is virtually no reimbursement for these products. At such a high cost, their growth is extremely limited to patients who can afford them. Success in this market will depend upon whether companies can get reimbursement for these products. Furthermore, market growth resulting from any future approvals is expected to be small, as bone-anchored hearing aids already treat mixed and conductive hearing loss and are much less expensive. Any share in that particular market must be won by quality and patient satisfaction, which is expected to be high with middle ear treatment. MEIs can further be broken up into fully-implantable and semi-implantable devices.
To access full report with TOC, please visit US Market Report for Middle Ear Implants 2017 - MedCore
Semi-implantable devices consist of three components: a magnetic part implanted onto the ossicles of the ear, a receiver, and a processor. The processor receives and communicates the sound vibrations by transforming the vibrations into electrical signals. An electromagnetic field is created that causes vibration of the bones of the middle ear in a manner that is similar to normal hearing. There are currently two FDA approved semi-implantable devices: The Vibrant Soundbridge (Med-El) and the Maxum implant (Ototronix). ,Middle ear implants (MEIs) are a relatively newer entrant into the hearing device market. MEIs are designed for people who cannot use or are dissatisfied with conventional hearing aids. MEIs are used on people who have moderate to severe sensorineural hearing loss or conductive/mixed hearing loss. While the technology uses a direct drive similar to those of percutaneous bone conduction system, it is distinct in both its designed indication as well as its function.
Scope
2013-2023
2013-2023
Companies Mentioned
Phonak Starkey Cochlear Oticon Sivantos Rayovac GN ReSound MED-EL Widex VARTA Unitron Advanced Bionics Duracell Sophono ZeniPower Energizer Maico Grason-Stadler Interacoustics MedRx Natus Audioscan GN Otometrics Benson Medical Instruments Intelligent Hearing Systems Tremetrics Welch Allyn Frye Electronics Ambco Envoy Medical Ototronix Heine Others include: Advanced Monitors Corporation, Ambco, American Diagnostics, Amplivox, Audina, Audioscan, Auditdata, Benson Medical Instruments, Duracell, e3 Audiometrics, Foster Special Instruments, Frye Electronics, GlobalMed Telemedicine, GN Otometrics, Grason-Stadler, Hansaton, Hear Clear, Heine, iCellTech, Intelligent Hearing Systems, Interacoustics, Inventis, KaWe, Madsen, Maico, MEDca, MedRx, Micro Audiometrics Corp, MicroTech, Natus, NEXcell, Otovation, Panasonic, Path Medical, Persona Medical, Renata, Riester, Rion, SeboTek Hearing Systems, Songbird Hearing, Sony, SoundHawk, Toshiba, Tremetrics, US Ophthalmic, Vivosonic, Welch Allyn, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment